← Eichor
Condition: Cart Therapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cart Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of AZD0754 in Participants With Metastatic Prostate Cancer
Phase 1/Phase 2 · 15 location(s) · AstraZeneca · NCT06267729uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Phase 1/Phase 2 · 1 location(s) · University of Colorado, Denver · NCT04544592Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947473Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
Phase 1 · 9 location(s) · Sonoma Biotherapeutics, Inc. · NCT06201416A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Disease
Phase 1 · 13 location(s) · Arcellx, Inc. · NCT06626919A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi
Phase 3 · 138 location(s) · AstraZeneca · NCT07391657MB-CART2019.1 in Refractory Multiple Sclerosis
Phase 1/Phase 2 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT07178431Genetically Modified T Cells Against Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT03184753Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106723Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch
Phase 3 · 3 location(s) · Chelsea and Westminster NHS Foundation Trust · NCT04892654Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors
Phase 1/Phase 2 · 3 location(s) · Sun Yat-Sen University Cancer Center · NCT06836505Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older
Phase N/A · 2 location(s) · University of Zurich · NCT07309497Phase I Study of OriC902 in Treatment of Advanced HCC
Phase 1 · 2 location(s) · Peking University · NCT06891742Exploratory Clinical Study on the Safety of STR-P004
NA · 1 location(s) · Beijing GoBroad Hospital · NCT07143617Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06695013Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblas
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06608342Universal CAR-T Cells Targeting Multiple Myeloma
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT06006741CAR-T Cell Therapy for Desensitization in Kidney Transplantation
Phase 1 · 3 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06056102CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07538635Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06236139Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
Phase N/A · 1 location(s) · Insel Gruppe AG, University Hospital Bern · NCT06333275Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapi
NA · 2 location(s) · Peter MacCallum Cancer Centre, Australia · NCT07051525GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
Phase 1 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06875063CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Phase 1 · 1 location(s) · Nathan Denlinger · NCT06209619A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T
Phase 1/Phase 2 · 13 location(s) · Cabaletta Bio · NCT04422912Study of CAR-T Therapy in Older Patients
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT04300998Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
Phase 1 · 1 location(s) · Hadassah Medical Organization · NCT07333430A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06066346CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947460
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.